Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Equillium’s latest SEC disclosures can feel like parsing an entire immunology textbook. Clinical trial updates, milestone payments and patent discussions sprawl across hundreds of pages, while Form 4 insider trades often move the market before pivotal data drops. If you have ever searched “Equillium SEC filings explained simply� or asked, “Where do I find Equillium’s quarterly earnings report 10-Q filing?�, you know the challenge.
Stock Titan solves that problem with AI-powered summaries that translate dense language into clear takeaways. Our platform tracks every submission in real time�10-K annual reports, 10-Q quarterly earnings, 8-K material events, S-3 financings and the Equillium proxy statement executive compensation tables. Need to monitor “Equillium insider trading Form 4 transactions� or get an alert on “Equillium Form 4 insider transactions real-time�? We surface who bought, who sold, and why it matters. Interactive dashboards connect clinical spending from the 10-Q to risk factors in the 10-K, giving you an integrated view without wading through footnotes.
Whether you are comparing R&D burn rates, timing catalytic trial readouts or evaluating dilution risk, our coverage keeps you ahead. Quickly scan an “Equillium earnings report filing analysis�, dig into “Equillium annual report 10-K simplified�, or see “Equillium 8-K material events explained� moments after they hit EDGAR. With AI guidance for understanding Equillium SEC documents with AI, professional investors, analysts and healthcare specialists gain the clarity needed to act confidently.
On August 4 2025, Rand Capital Corporation filed an 8-K to furnish materials related to its second-quarter 2025 results. Under Item 2.02, the Company states that it has issued a press release (Exhibit 99.1) announcing Q2 results; however, the filing itself does not include any financial metrics. Under Item 7.01, Rand notes that an updated slide deck used for the earnings conference call will be posted in the Investor section of its website. Both disclosures are expressly furnished—not filed—so they carry no Section 18 liability and are excluded from automatic incorporation by reference.
No other material events, transactions, or quantitative data are presented in this report.
Equillium, Inc. (NASDAQ: EQ) has filed a Form 144 indicating a proposed insider sale. Affiliate Jason Andrew Keyes plans to dispose of up to 88,913 common shares through broker Maxim Group on or about 07 July 2025. The filing lists an aggregate market value of $28,452.16, implying a reference price near $0.32 per share. Equillium has 35.72 million shares outstanding; the planned sale therefore represents roughly 0.25 % of the float, a modest fraction unlikely to create meaningful dilution.
The seller acquired the shares on 29 June 2018 via the company’s Employee Stock Purchase Plan and paid cash. Over the past three months, Keyes has already sold 10,000 shares on 12 June 2025 for gross proceeds of $3,860 (about $0.39 per share). The Form 144 includes the customary representation that the filer is unaware of undisclosed material adverse information about Equillium.
While Form 144 notices are routine for insiders wishing to avail themselves of Rule 144 resale exemptions, investors often monitor them for sentiment clues. The limited size of this transaction and the relatively low dollar amount suggest minimal direct market impact, though persistent insider selling may weigh on investor perception.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
What is the primary focus of Equillium Inc?
Which therapeutic targets does Equillium utilize in its pipeline?
How does Equillium differentiate itself from other biotech companies?
What types of therapies is Equillium developing?
What role does research and development play in Equillium's business model?
How does Equillium ensure the integrity of its clinical studies?
